News
Study reveals new data on the magnitude of antibiotic resistance
Antibiotic resistance is one of the greatest public health challenges worldwide, and its effects not only affect humans, but also animals and livestock. A recent study published in the journal Microbial Pathogenesis sheds new light on the magnitude of this…
Nature as a source of innovation
Nature has been, and continues to be, an inexhaustible source of inspiration and solutions for human health. One need only look at the history of modern medicine to understand the enormous impact that natural compounds have had on drug development.…
This is what makes Hifas Biologics different
At HIFAS Biologics, every step we take is driven by a commitment to finding innovative solutions against microbial resistance. Our unique approach and strategies are designed to revolutionize the development of new fungal-based antibiotics. With a talented, multidisciplinary team, we…
Which came first, antibiotics or resistant bacteria?
The question of whether antibiotics or resistant bacteria appeared first seems to have an obvious answer: resistance should develop after exposure to antibiotics, right? However, recent research in unexplored places, such as Lechuguilla Cave in New Mexico, has challenged this…
Our activotheque: a key element
At HIFAS Biologics, one of our core values is the activotheque, a unique platform that drives our research in discovering new medicines derived from fungi. This approach not only strengthens our commitment to innovation but also integrates effectively with the…
Bacterial resistance: a global health challenge
Since the discovery of penicillin by Alexander Fleming in 1928, humanity has witnessed an alarming phenomenon: bacteria have developed the ability to resist a wide range of antibiotics. This phenomenon, known as microbial resistance, represents one of the most significant…
Albert Neisser and the fight against gonorrhea
108 years ago, a German physician named Albert Neisser first identified the pathogen that causes gonorrhea, Neisseria gonorrhoeae. This pioneering work, dated 1879, not only marked a milestone in microbiology, but also set a precedent for the research and treatment…
Active samples against cryptococcus neoformans
Cryptococcus neoformans is one of our focuses at HIFAS Biologics: an encapsulated fungus that causes cryptococcosis, a serious disease with high mortality rates, especially among HIV-infected patients. The problem lies in the fact that, in recent years, this pathogen has…
Novopam, new antimicrobial peptides from fungi
En la actualidad, la resistencia antimicrobiana es uno de los mayores desafíos de la medicina moderna. La eficacia de muchos fármacos está disminuyendo rápidamente debido a la adaptación de las bacterias, lo que complica el tratamiento de infecciones y plantea…
News for Helicobacter Pylori: the crucial role of biofilms in its resistance
In the ongoing fight against bacterial resistance, every advance is crucial to developing more effective treatments. A recent study published in the journal DovePress has shed new light on the ability of Helicobacter pylori bacteria to form biofilms and how…
The team at HIFAS Biologics: the force behind innovation
At HIFAS Biologics, we are convinced that the true power of a company lies in the brilliant and dedicated minds that compose it. Our highly skilled, multidisciplinary team is the key to advancing the frontier of science and tackling microbial…
Staphylococcus Aureus and the beginnings of bacterial resistance
When it comes to identifying the most critical challenges in modern medicine, we at Hifas Biologics have a very clear answer: bacterial resistance is undoubtedly at the top of the list. That is why we have taken on the responsibility…
Innovative strategy: Advancing new drug discovery
If there is one thing that is clear to us at Hifas Biologics, it is that the world of fungi is an invaluable source of innovation in the discovery of new drugs, especially in the fight against multi-resistant bacterial strains.…
How to differentiate between the terms antimicrobial and antibiotic?
At HIFAS Biologics, we understand that the fight against microbial resistance can be confusing due to the variety of technical terms used. Two frequently confused terms are antimicrobial and antibiotic. Although both relate to the treatment of infections, they have…
Penicillin: a turning point for global health
Imagine living in a world without antibiotics and effective treatments for infections. Before the discovery of penicillin in 1928, this was the harsh reality facing humanity. Infant Mortality and Infectious Diseases Before penicillin, bacterial infections were often a death sentence.…
Louis Pasteur, a key player in the fight against infectious diseases
Louis Pasteur, a 19th century French chemist and biologist, challenged the prevailing scientific beliefs of his time and set a turning point in the conceptualization of medicine and the treatment of infectious diseases. Until the mid-19th century, the theory of…
Innovation for antimicrobial resistance: the HIFAS Biologics approach
The fungal world is an inexhaustible source of innovation for the early discovery of targeted drugs against multidrug-resistant bacterial strains. Our approach at HIFAS Biologics is based on the exploration of fungi and their ability to produce bioactive compounds with…
“Hyphae” in HIFAS Biologics, much more than a name
At HIFAS Biologics we have a clear mission and a very specific goal: to combat microbial drug resistance by researching and developing new antibiotics from fungi. But have you ever wondered what our company name means? Beyond being a simple…
AI: an ally in the fight against antibiotic resistance
AI has been on everyone’s lips for a few years now. And, unsurprisingly, this technology that promises to revolutionize the world with its capacity for iterative improvement has also reached the microbial control sector: an article published less than two…
WHO priority pathogens list 2024 published
The World Health Organization’s (WHO) list of priority pathogens has been published! Just a few weeks ago, the World Health Organization published the “Bacterial Priority Pathogens List 2024”. This highly significant document for the microbial control sector identifies the key…
Key terms in the fight against microbial resistance: Germ vs Pathogen
Have you ever had doubts when using different terms in the fight against microbial resistance? Do you know what is the clear difference between germ and pathogen? Don’t worry! At HIFAS Biologics, we help you to put an end to…
The medicinal potential of endolytic fungi in bioactive mushroom metabolites
The journal Fungi Bioactive Metabolites has recently published research highlighting the therapeutic potential of endolytic fungi. In this study, 108 different species of these fungi were analysed, revealing their unique bioactivities and therapeutic attributes. But what are endolytic fungi? Endolytic…
Our strategy to combat microbial resistance: fungus-driven innovation
The fungal world represents an invaluable source of innovation for early drug discovery targeting multi-resistant bacterial strains. That is our philosophy at HIFAS Biologics. Therefore, our strategy is entirely focused on the research and development of new antibiotics and is…
HIFAS Biologics finalist of the INNOVATE4TOMORROW programme
At HIFAS Biologics we are celebrating! We are very pleased to announce that HIFAS Biologics has been selected as one of the finalists in the INNOVATE4TOMORROW programme, organised by Ayming. This flagship industry programme aims to recognise and reward innovative…
HIFAS Biologics participates in the Galicia Biodays 2024
Although we are back, at HIFAS Biologics we are still excited about what we experienced last week at Galicia Biodays 2024. Our team travelled to the Mar de Vigo Auditorium, in the heart of the Olívica City, on 12 and…
HIFAS Biologics and IPNA: a promising collaboration for innovation in biotechnology
New collaboration project for HIFAS Biologics! We are very excited to announce our latest collaborative project: this time with the Institute of Natural Products and Agrobiology (IPNA). This partnership represents a significant step in our mission to tackle microbial resistance.…
Four facts you might not have known about mushrooms
Think you know all about mushrooms? At HIFAS Biologics, our mission is focused on combating antibiotic resistance by using the power of fungi to develop new drugs capable of effectively tackling these resistant pathogens. Our little (or not so little)…
HIFAS Biologics in the Biotech Startup Acceleration Program
At Hifas Biologics, we are excited to share one of our most recent and significant achievements: we have been selected to participate in the Biotech Startups Acceleration Programme, a collaborative initiative of the EOI Foundation and the Ministry of Industry,…
Debunking common myths about fungi in the pharmaceutical industry
Over the years, fungi have been the subject of numerous myths and misunderstandings in the context of the pharmaceutical industry. At HIFAS Biologics, we are committed to separating fact from fiction and providing a clear perspective on the vital role…
Why should you be concerned about antimicrobial resistance?
Although it may seem a distant, distant or alien topic, antimicrobial resistance has become a global public health issue. The reality is harsher than it appears: we are all at risk and can all be affected by this growing threat.…
Global Health Challenges: Addressing the antimicrobial resistance crisis
There is a challenge that has captured the attention of most experts in the field of global health: antimicrobial resistance. This growing trend towards antibiotics and drugs that are ineffective against current pathologies poses a serious obstacle to the treatment…
Thousands of unknown mushroom species: a unique therapeutic offering
Did you know that there are still thousands of mushroom species yet to be discovered? This huge statistic highlights the wide range of fungi types still unknown and, consequently, the possibility that among them may hide an enormous therapeutic opportunity…
Why does antimicrobial resistance occur?
Antimicrobial resistance has become a topical issue of growing concern. The appearance of cases where drugs are not completely effective against certain pathologies has been increasing over the last few years, putting the public health welfare in the spotlight. Under…
Challenging antibiotic resistance: Fungi against pneumonia, gonorrhoea and intestinal diseases
In the modern era of medicine, advances in antibiotics have saved countless lives, effectively treating diseases caused by pathogens such as Streptococcus pneumoniae, Neisseria gonorrhoeae and Campylobacter Jejuni. However, these micro-organisms, which are responsible for serious diseases such as pneumonia,…
Drug development against antimicrobial resistance
In the battle against infectious diseases, antimicrobial resistance is in the spotlight: it has become a growing and worrying challenge. Therefore, at HIFAS Biologics we have a strong commitment to tackle this problem by developing new fungal-derived antibiotics. But how…
HIFAS Biologics and “One Health”: An alliance to defend public health
In the 21st century, the accelerating pace of globalisation, climate change and urbanisation has brought public health concerns into the spotlight. The connection between human and environmental health has become more evident than ever, demonstrating that any disruption to an…
Hifas Biologics and the CSIC join forces in an innovative collaboration to develop antimicrobial peptides to fight multidrug-resistant infections
Hifas Biologics, a leader in the early development of antimicrobials from fungi, is proud to announce an exciting collaboration with the Spanish National Research Council (CSIC) specifically with the IPNA (Institute of Natural Products and Agrobiology). This strategic partnership, which…
Hifas Biologics joins the prestigious biotechnology startup acceleration program “SiloAceleraBio” coordinated by SILO in collaboration with ASEBIO.
Hifas Biologics, a leading company in the early development of antimicrobials from fungal origin, has been selected to participate in the renowned biotechnology company acceleration program “SiloAceleraBio”. This inclusion in SiloAceleraBio marks a significant milestone for Hifas Biologics, consolidating its…
The growing concern about antibiotic resistance opens the door to a new model of financing and disruptive strategies for obtaining them
Advances in studies of the One Health approach have fostered greater awareness that antibiotic resistance is a major problem. Nevertheless, the low profitability of the antibiotic development process has meant that SMEs are currently the only ones carrying out this…
La OMS publica el Programa de Investigación Prioritaria sobre la Resistencia a los Antimicrobianos (RAM)
Este programa de investigación primaria engloba a la Organización de las Naciones Unidas para la Agricultura y la Alimentación (FAO), el Programa de las Naciones Unidas para el Medio Ambiente (PNUMA), la División de RAM de la Organización Mundial de…
40 priority research topics will form the basis of the policy-directive-technical guide on antimicrobial resistance in 2030
Antimicrobial resistance in the human health sector is the priority focus of the global research agenda, which is centered on 40 research themes concerning WHO’s priority bacterial and fungal pathogens of critical importance for antimicrobial resistance, as well as drug-resistant…
Six decades without new drugs to combat bacterial resistance
Bacteria are developing increasing resistance to drugs, and the lack of innovation in antimicrobial medications has been evident for decades. Antimicrobial resistance poses a significant threat to public health worldwide. Most of the antibiotics currently available on the market are…
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Antimicrobial resistance (AMR) poses a significant threat to human health worldwide. Previous articles, prior to the one published in January 2022 in The Lancet, have estimated the impact of AMR on disease incidence, mortality rates, hospitalization durations, and healthcare costs…